Our analysis of five clinical trials in which 5,757 subjects were grouped has shown that this intervention reduces the risk of gastric cancer. The relative risk 0.57 CI = 0.42- 0.79 suggests that eradication is an effective measure for reducing the risk of gastric cancer and is statistically significant.
Analizando 5 experimentos clínicos, se agruparon 5.757 sujetos, mostrando que esta intervención reduce el riesgo de cáncer gástrico con un riesgo relativo 0,57 IC = 0,42-0,79, lo cual sugiere que la erradicación es una medida eficaz en la reducción del riesgo de cáncer gástrico y es estadísticamente significativa.